Treatment of lupus with corticosteroids

Lupus

Volumn 10, Issue 3, 2001, Pages 140-147

  Chatham, W W ^a   Kimberly, R P ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Corticosteroids; Lupus

Indexed keywords

CORTICOSTEROID; GLUCOCORTICOID RECEPTOR; TRANSCRIPTION FACTOR;

APOPTOSIS; ATHEROGENESIS; BONE NECROSIS; CELL ADHESION; CELL FUNCTION; DNA BINDING; DRUG EFFECT; GENE EXPRESSION; HUMAN; IMMUNE RESPONSE; IMMUNOGLOBULIN PRODUCTION; INFECTION SENSITIVITY; OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SURVIVAL RATE; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE;

ADRENAL CORTEX HORMONES; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC;

EID: 0035043299     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/096120301675075008     Document Type: Review

References (109)

1. Corticosteroids
2. Nuclear hormone receptors activate direct, inverted, and everted repeats
3. A negative regulatory region containing a glucocorticoid response element (nGRE) in the human interleukin-1 beta gene
4. Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids
5. Immunosuppression by glucocorticoids: Inhibition of NF-kappa B activity through induction of I kappa B synthesis
6. Regulation of cytokine and cytokine receptor expression by glucocorticoids
7. Transcriptional cross-talk, the second mode of steroid hormone receptor action
8. AP-1 function and regulation
9. A mechanism for the anti-inflammatory effects of corticosteroids: The glucocorticoid receptor regulates leukocyte adhesion to endothelial cells and expression of endothelial-leukocyte adhesion molecule 1 and intercellular adhesion molecule 1
10. Effects of corticosteroids on human monocyte function
11. Effects of corticosteroid therapy on human monocyte function
12. Prednisolone inhibits phagocytosis by polymorphonuclear leukocytes via steroid receptor-mediated events
13. Complement-independent clearance of IgG-sensitized erythrocytes: Inhibition by cortisone
14. Anti-inflammatory steroids induce synthesis of a phospholipase A2 inhibitor which prevents prostaglandin generation
15. A phospholipase A2 inhibitory protein in rabbit neutrophils induced by glucocorticoids
16. Macrocortin: A polypeptide causing anti-phospholipase effect of glucocorticoids
17. TNF-alpha-induced cyclooxygenase-2 expression in human lung epithelial cells: Involvement of the phospholipase C-gamma 2, protein kinase C-alpha, tyrosine kinase, NF-kappa B-inducing kinase, and I-kappa B kinase 1/2 pathway
18. The influence of prednisolone on the recirculation of peripheral blood lymphocytes in vivo
19. Glucocorticoid-induced apoptosis and regulation of NF-kappa B activity in human leukemic T-cells
20. Glucocorticosteroid-induced inhibition of T-cell growth factor production. I. The effect on mitogen-induced lymphocyte proliferation
21. Administration of prednisolone in vivo affects the ratio of OKT4/OKT8 and the LDH isoenzyme pattern of human T-lymphocytes
22. Prednisone induced alterations of circulating human lymphocyte subsets
23. Differential regulation of interleukin-10 (IL-10) and IL-12 by glucocorticoids in vitro
24. Corticosteroid effect on immunoglobulins
25. Effects of methylprednisolone on the in vivo induction and function of suppressor cells in man
26. Effect of high-dose methylprednisolone infusion on polymorphonuclear leukocyte function in patients with systemic lupus erythematosus
27. High dose intravenous methylprednislone 'pulse' therapy in patients with rheumatoid disease. Plasma methylprednisolone levels and adrenal function
28. Effects of corticosteroids on the human immune response: Comparison of one and three daily 1 gm intravenous pulses of methylprednisolone
29. Effects of corticosteroids on the human immune response: Suppression of mitogen induced lymphocyte proliferation by pulse methylprednisolone
30. Prolonged effects of large dose methylprednisolone infusion on multiple sclerosis
31. Corticosteroids inhibit complement-induced granulocyte aggregation
32. Pulse methylprednisolone in rheumatoid arthritis: Effects on peripheral blood and synovial fluid neutrophil surface phenotype
33. Lupus pernio: Successful treatment with a potent topical corticosteroid
34. Cardiac abnormalities in SLE: Pancarditis
35. The spectrum of pericardial tamponade in systemic lupus erythematosus. Report of ten patients
36. Acute lupus peritonitis successfully treated with steroid pulse therapy
37. Chronic lupus peritonitis with ascites
38. Reversible thickening of the bowel and urinary bladder wall in systemic lupus erythematosus: A case report
39. Interstitial lung disease in systemic lupus erythematosus
40. Pulmonary hemorrhage in systemic lupus erythematosus
41. Treatment of hemorrhagic lupus pneumonitis with plasmapheresis
42. Bronchiolitis obliterans organizing pneumonia as an initial manifestation in patients with systemic lupus erythematosus
43. Cytomegalovirus-induced interstitial pneumonitis in a patient with systemic lupus erythematosus
44. Pneumocystis carinii pneumonia in the course of connective tissue disease: Report of 34 cases
45. Pneumocystis carinii pneumonia complicating selective CD4 T-cell depletion induced by corticosteroid therapy in a patient with systemic lupus erythematosus
46. Patients with systemic lupus erythematosus at risk for Pneumocystis carinii pneumonia
47. The effect of large doses of prednisone on the renal lesions and life span of patients with lupus glomerulonephritis
48. The natural history of the renal manifestations of systemic lupus erythematosus
49. Renal insufficiency in lupus nephritis
50. High-dose intravenous methylprednisolone pulse therapy in systemic lupus erythematosus
51. Reversible 'endstage' lupus nephritis. Analysis of patients able to discontinue dialysis
52. Beneficial effects of methylprednisolone 'pulse' therapy in diffuse proliferative lupus nephritis
53. Methylprednisolone pulse therapy for lupus nephritis: A follow-up study
54. Treatment of diffuse proliferative lupus nephritis by intravenous high-dose methylprednisolone
55. Monthly pulses of methylprednisolone in SLE nephritis
56. Kidney disease in systemic lupus erythematosus
57. Systemic lupus erythematosus: Emerging concepts. Part 1: Renal, neuropsychiatric, cardiovascular, pulmonary, and hematologic disease
58. Migrainous phenomena in systemic lupus erythematosus
59. The management of systemic lupus erythematosus
60. Central nervous system disease in systemic lupus erythematosus
61. Chorea as the presenting clinical feature of primary antiphospholipid syndrome in childhood
62. Chorea in the antiphospholipid syndrome. Clinical, radiologic, and immunologic characteristics of 50 patients from our clinics and the recent literature
63. Neurologic characteristics of childhood lupus erythematosus
64. Transverse myelopathy in systemic lupus erythematosus: An analysis of 14 cases and review of the literature
65. Favorable response to intravenous methylprednisolone and cyclophosphamide in children with severe neuropsychiatric lupus
66. Acute transverse myelopathy in systemic lupus erythematosus: Clinical presentation, treatment, and outcome
67. Use of cyclophosphamide in the treatment of thrombotic thrombocytopenic purpura complicating systemic lupus erythematosus: Report of two cases
68. Thrombotic thrombocytopenic purpura in systemic lupus erythematosus and antiphospholipid antibodies: Effective treatment with plasma exchange and immunosuppression
69. Corticosteroids and systemic lupus erythematosus pancreatitis: A case series
70. Massive gastrointestinal hemorrhage in systemic lupus erythematosus: Successful treatment with corticosteroid pulse therapy
71. CT findings at lupus mesenteric vasculitis
72. Clinical features of lupus myositis versus idiopathic myositis: A review of 30 cases
73. Lupus erythematosus and dermatomyositis
74. Alternate day corticosteroid therapy
75. Alternate-day prednisone. Leukocyte kinetics and susceptibility to infections
76. Perioperative glucocorticoid coverage: A reassessment 42 y after emergence of a problem
77. Prednisone for chronic active liver disease: Pharmacokinetics including conversion to prednisolone
78. Corticosteroids in liver disease: Studies on the biological conversion of prednisone to prednisolone and plasma binding protein
79. Prednisone or prednisolone for the treatment of chronic active hepatitis? A comparison of plasma availability
80. Boston collaborative drug surveillance program: Prednisone side effects and serum protein levels, a collaborative study
81. Studies on dexamethasone metabolism in man: Effect of diphenylhydantoin
82. Effects of diphenylhydantoin, phenobarbital, and diazepam on the metabolism of methylprednisolone and its sodium succinate
83. Effectiveness of prednisolone during phenytoin therapy
84. Computer analysis of factors influencing frequency of infection in systemic lupus erythematosus
85. Incidence of infection in systemic lupus erythematosus
86. Pneumocystis carinii pneumonia: A comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies
87. Patients with systemic lupus erythematosus at risk for Pneumocystis carinii pneumonia
88. Systemic lupus erythematosus: Mortality and survival in Argentina. A multicenter study
89. Systemic lupus erythematosus: Demographics, prognosis, and outcome
90. Acute adverse reactions to prednisone in relation to dosage
91. Presentation of the steroid psychoses
92. Side effects of corticosteroid therapy. Psychiatric aspects
93. Steroid myopathy: Clinical, histologic and cytologic observations
94. Steroid myopathy in connective tissue disease
95. Vacuolar myopathy in a patient with a positive LE cell preparation
96. Acute pancreatitis in SLE: Report of 20 cases and a review of the literature
97. Drug-induced pancreatitis: A critical review
98. Risk factors for avascular bone necrosis in systemic lupus erythematosus
99. Risk factors for osteonecrosis in systemic lupus
100. Avascular osteonecrosis in patients with SLE: Relation to corticosteroid therapy and anticardiolipin antibodies
101. Ischemic necrosis of bone in systemic lupus erythematosus
102. Aseptic necrosis of bone in systemic lupus erythematosus
103. Longitudinal analysis of bone mineral density in premenopausal femal systemic lupus erythematosus patients: Deleterious role of glucocorticoid therapy at the lumbar spine
104. Bone mineral density in systemic lupus erythematosus: Comparison with rheumatoid arthritis and healthy controls
105. SLE and osteoporosis: Dependence and/or independence on glucocorticoids
106. Bone loss in adults receiving alternate day glucocortoid therapy: A comparison with daily therapy
107. Osteopenia in young hypogonadal women with systemic lupus erythematosus receiving chronic steroid therapy: A randomized controlled trial comparing calcitriol and hormonal replacement therapy
108. Hormone replacement therapy in postmenopausal women with systemic lupus erythematosus
109. The association of dehydroepiandrosterone sulphate levels with bone mineral density in systemic lupus erythematosus